Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common ADHD drug truly sharpen a healthy mind? a trial puts it to the test

NCT ID NCT07742631

Knowledge-focused Sponsor: University of Witwatersrand, South Africa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial asks whether methylphenidate, a stimulant used for ADHD, can actually improve thinking, exercise capacity, balance, and heart safety in healthy adults without ADHD. About 30 healthy volunteers aged 18 to 50 will take either the drug or a placebo for 14 days, then switch after a break. Researchers will measure attention, oxygen use during exercise, heart rhythm, and muscle strength to see if the drug offers any real benefit beyond a placebo effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extended-release methylphenidate (a stimulant medication) taken as 20 mg capsules once daily for 14 days, compared with an inert placebo.
What this could lead to
If it works, this could clarify whether methylphenidate truly boosts mental or physical performance in healthy people, or if the perceived benefits are mostly placebo effects.
What could go wrong
This is a small, early-phase trial in healthy volunteers, so results may not apply to real-world use. Methylphenidate can raise heart rate and blood pressure, and its cognitive benefits in non-ADHD adults remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

30 people

The number who actually took part.

Started

Feb 2023

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults without a diagnosis of ADHD * Age 18 to 50 years * Willing to participate after being informed about the study * Willing to receive both methylphenidate and placebo during the study period * Willing to undergo non-invasive physiological, cognitive, cardiovascular, balance, and physical performance assessments * Able to comply with all study procedures and visits Exclusion Criteria: * Current use of any medication that may affect cognitive performance, physical performance, electrocardiogram (ECG) findings, cardiovascular function, or balance * Any medical, neurological, musculoskeletal, psychiatric, or other condition that may interfere with the safe or successful completion of study assessments and physical performance testing * Any contraindication to methylphenidate administration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adult male and female volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy adult male and female volunteers

Contacts and locations

Locations

  • University of the Witwatersrand

    Johannesburg, Gauteng, 2193, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.